TransMolecular, Inc. Announces Formation of Medical Advisory Board
TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the formation of a Medical Advisory Board. The Medical Advisory Board, comprised of six expert clinicians and scientists in the oncology field, will advise the Company on its clinical development programs.
“The creation of a strong, influential Medical Advisory Board highlights our commitment to the advancement and expansion of our clinical development programs for difficult-to-treat cancers, and we look forward to working closely with these individuals to refine and execute on our strategy,” said Michael Egan, President and Chief Executive Officer of TransMolecular. “We are encouraged by positive interim data from our Phase 2 trial of radiolabeled TM-601 administered intracavitarily in patients with recurrent malignant glioma, and we are also encouraged by our Phase 1 study of intravenous radiolabeled TM-601 in a variety of refractory metastatic solid tumors, including malignant glioma. We look forward to presenting data from these trials at the American Society for Therapeutic Radiology and Oncology (ASTRO) and the Society for Neuro-Oncology (SNO) medical meetings this fall. Also, we anticipate starting soon a Phase 1 trial with a non-radiolabeled version of TM-601 for malignant glioma, which demonstrates the multiple applications possible from this therapeutic platform.”
The founding members of TransMolecular’s Medical Advisory Board include Lewis C. Cantley, Ph.D.; Patricia A. D’Amore, Ph.D.; John K. Erban, M.D.; William C. Hahn, M.D. Ph.D.; Jay S. Loeffler, M.D.; and Ralph R. Weichselbaum, M.D.
About the Medical Advisory Board
Lewis C. Cantley, Ph.D., is currently a Professor of Systems Biology at Harvard Medical School and is Chief, Division of Signal Transduction in the Department of Medicine, Beth Israel Deaconess Medical Center. His research focus is on the biochemical basis for growth, survival and transformation of mammalian cells, and he is credited with the discovery of the phosphoinositide 3-kinase (PI3K) pathway. Dr. Cantley has authored over 300 original publications, and is on the editorial boards of the Journal of Cell Biology and Cell. He holds a Ph.D. in Biophysical Chemistry from Cornell University and a B.S. in Chemistry from Wesleyan College.
Patricia A. D’Amore, Ph.D., is currently Professor in the Department of Ophthalmology and Pathology at Harvard Medical School, the Associate Director of Research and the Ankeny Scholar of Retinal Molecular Biology at Schepens Eye Research Institute, and also serves as a Research Associate in the Department of Surgery at Children’s Hospital Boston. Her research is focused on vascular development and growth control, and she has been an author on 113 original research articles. Dr. D’Amore holds an MBA from Northeastern University, a Ph.D. in Biology from Boston University, and B.A. from Regis College.
John K. Erban, M.D., currently serves as Director of Clinical Programs and Co-Director, Gillette Center for Breast Cancer at Massachusetts General Hospital. He has held academic appointments at both Harvard University Medical School and Tufts University School of Medicine. He has authored approximately 50 original articles, reviews, chapters and editorials, and has served as a member of the editorial boards of the Journal of Clinical Oncology and Oncology, Index and Reviews. He holds an M.D. from Tufts University School of Medicine and an A.B. from Harvard University.
William C. Hahn, M.D., Ph.D., is an Associate Professor of Medicine in the Department of Medical Oncology, Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, and is also an Associate Physician in the Department of Medicine at Brigham and Women’s Hospital. He is an author on over 100 original articles, reviews, chapters and editorials. Dr. Hahn is on the editorial boards of Cancer Biology and Therapy, Cell Cycle, and Carcinogenesis; is the Associate Editor of Cancer Research; and is the Section Editor of Biochimica et Biophysica Acta Reviews on Cancer. He holds his Ph.D., M.D., and A.B. from Harvard University.
Jay S. Loeffler, M.D., serves as Chief of the Department of Radiation Oncology at Massachusetts General Hospital, and is also a Herman and Joan Suit Professor of Radiation Oncology at Harvard Medical School. He is also Chairman of the Executive Committee in the Department of Radiation Oncology, Harvard Medical School. Dr. Loeffler’s research interests centered on brain tumors, including glioma, as well as on radiotherapy. He has been an author on over 300 original articles, reviews, chapters and editorials. Dr. Loeffler received his M.D. from Brown University School of Medicine and his B.A. from Williams College.
Ralph R. Weichselbaum, M.D., is the Daniel K. Ludwig Professor of Radiation Oncology and Chairman, Department of Radiation and Cellular Oncology, at the University of Chicago Pritzker School of Medicine, and is also Head of the University of Chicago Center for Radiation Therapy and Director of the Chicago Tumor Institute. Dr. Weichselbaum’s research interests include head and neck cancer treatments, radiotherapy, ionizing radiation, and anti-angiogenic therapy. He is listed on dozens of patents and pending patents, and has been an author on more than 600 publications. He holds an M.D. from the University of Illinois and a B.S. from the University of Wisconsin.
About TransMolecular, Inc.
TransMolecular, Inc. is a privately held, venture capital backed biotechnology company committed to discovering, developing and commercializing novel and proprietary products to diagnose and treat cancers that have inadequate treatment alternatives. TransMolecular’s product pipeline is based on a protein platform that employs therapeutically active polypeptides derived from scorpion venom. The company is currently exploring the use of this platform for broad applications to diagnose and treat cancers and other human diseases. More information can be found at www.transmolecular.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, intellectual property, and other factors.